Erasca, Inc. (NASDAQ:ERAS) is one of the best performing healthcare stocks so far in 2026.
The Fly reported on May 4 that JPMorgan is maintaining an Overweight rating on Erasca, Inc. (NASDAQ:ERAS) and recommends buying the stock at current levels
The firm believes that the stock boasts several catalysts over the coming months and believes that the recent weakness in its shares is overdone. JPMorgan further told investors in a research note that ERAS-0015 has potential for safety differentiation and looks efficacious in non-small cell lung cancer. Erasca, Inc. (NASDAQ:ERAS) also received a rating update from H.C.
Wainwright on April 28. The firm maintained a Buy rating on the stock with a $20 price target, with the rating coming after the company reported preliminary Phase 1 data for ERAS-0015. H.C.